Hamburg, Germany - 16 October 2013: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA. At the meeting, Evotec will provide an overview of the Company's systematic, unbiased and comprehensive drug discovery infrastructures and its core disease areas.

Furthermore, Prof Dr Doug Melton will hold a presentation on regenerative medicine regarding beta cell function.

Evotec R&D Day 2013

Date: Tuesday, 22 October 2013, 11:30 am EST (04:30 pm GMT, 05:30 pm CET)
Venue: New York, NY, USA
Presenter:         
Dr Werner Lanthaler, Chief Executive Officer of Evotec
Dr Cord Dohrmann, Chief Scientific Officer of Evotec
Prof Dr Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator
There will be a live webcast of this event: http://evotec.equisolvewebcast.com/rd-day. The PDF version of the presentation will be provided at www.evotec.com shortly before the event. 

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.